HBI-8000-303 evaluates the HDAC inhibitor HBI-8000 plus nivolumab in advanced melanoma, examining PFS, response, safety, and ...

DESTINY-Breast05 shows T-DXd maintained overall HRQoL versus T-DM1 while previously reducing invasive recurrence or death by ...

Georgiamune Signs $1.1 Billion Global Licensing Deal With MENARINI Group - Parker Institute / cancer, Georgiamune, MENARINI ...

Looking Forward to See Precision Cancer Vaccine Trial Results at ESMO 2026 / esmo 2026, ESMO conference, ESMO26, European ...

AORTIC- Africa Launches 2026 - 2027 Cancer Awareness Campaign / Abidemi Omonisi, Adamu Addisie, Ahmed Elzawawy, AORTIC Africa ...

Azenosertib Shows 15.8-Month Overall Survival in Cyclin E1-Positive Ovarian Cancer / Azenosertib, biomarker-driven therapy, ...

FOLFIRI Plus Ramucirumab Versus Paclitaxel Plus Ramucirumab in Advanced Gastroesophageal Adenocarcinoma / Advanced ...

SHR-A2102 at ESMO 2026 Shows 47.2% Response Rate in Recurrent or Metastatic Cervical Cancer / cancer, ESMO, esmo 2026, ...

UV1 Vaccine Plus Olaparib and Durvalumab Shows PFS Signal in Ovarian Cancer / BRCA-Wildtype, cancer, cancer vaccines, DOVACC ...

Shows 52.9% Response Rate in Pretreated Cervical Cancer / cancer, ESMO, esmo 2026, ESMO2026, JSKN033, JSKN033-102 Trial, ...

HORIZON-Breast06 shows trastuzumab rezetecan prolonged PFS to 16.4 months versus 6.8 months in HER2-low advanced breast ...

Plasma ctDNA for HRR and PI3K/AKT Genotyping in mCRPC / cancer, cancer care, Cancer research, cancer treatment, clinical ...